Abstract：
The landscape of melanoma treatment has undergone a dramatic revolution in the past decade. The use of oncolytic viruses (OVs) represents a novel therapeutic approach that can selectively infect and lyse tumor cells and induce local and systemic antitumor immune responses. As the first OV approved by the Food and Drug Administration (FDA) for melanoma treatment, talimogene laherparepvec (T-VEC), a genetically modified herpes simplex virus (HSV), has shown promising therapeutic effects in the treatment of advanced melanoma, both as a monotherapy or in combination with other immunotherapies, such as the immune checkpoint inhibitors (ICIs). With proven efficacy, T-VEC has been evaluated against a variety of other cancer types in a clinical trial setting. In this article, we will provide a review on OVs and the application of T-VEC in melanoma monotherapy and combination therapy. In addition, we will review the recent progress of T-VEC application in other cutaneous cancer types. Moreover, we will briefly describe our experience of T-VEC therapy at City of Hope, aiming to provide more insight for expanding its future application.
摘要：
在过去的十年中，黑色素瘤治疗的前景经历了一场戏剧性的革命。溶瘤病毒（OVs）的使用代表了一种新颖的治疗方法，可以选择性地感染和裂解肿瘤细胞并诱导局部和全身抗肿瘤免疫反应。作为食品和药物管理局（FDA）批准用于黑色素瘤治疗的第一个OV，talimogenelaherparepvec（T-VEC），转基因单纯疱疹病毒（HSV），在晚期黑色素瘤的治疗中显示出有希望的治疗效果，作为单一疗法或与其他免疫疗法组合，例如免疫检查点抑制剂(ICIs)。经过验证的疗效，T-VEC已在临床试验环境中针对多种其他癌症类型进行了评估。在这篇文章中,我们将对OVs以及T-VEC在黑色素瘤单一治疗和联合治疗中的应用进行综述.此外,我们将综述T-VEC在其他类型皮肤癌中的应用进展。此外，我们将简要描述我们在希望之城接受T-VEC治疗的经验，旨在为扩展其未来应用提供更多见解。
